ARAY vs. ANGO, SRDX, CTSO, OFIX, RCEL, UTMD, PROF, DRTS, TLSI, and OBIO
Should you be buying Accuray stock or one of its competitors? The main competitors of Accuray include AngioDynamics (ANGO), Surmodics (SRDX), Cytosorbents (CTSO), Orthofix Medical (OFIX), AVITA Medical (RCEL), Utah Medical Products (UTMD), Profound Medical (PROF), Alpha Tau Medical (DRTS), TriSalus Life Sciences (TLSI), and Orchestra BioMed (OBIO). These companies are all part of the "surgical & medical instruments" industry.
Accuray (NASDAQ:ARAY) and AngioDynamics (NASDAQ:ANGO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, community ranking, dividends, valuation, institutional ownership and earnings.
Accuray has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500. Comparatively, AngioDynamics has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500.
Accuray has higher revenue and earnings than AngioDynamics. Accuray is trading at a lower price-to-earnings ratio than AngioDynamics, indicating that it is currently the more affordable of the two stocks.
64.1% of Accuray shares are owned by institutional investors. Comparatively, 89.4% of AngioDynamics shares are owned by institutional investors. 3.8% of Accuray shares are owned by insiders. Comparatively, 5.1% of AngioDynamics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, Accuray had 17 more articles in the media than AngioDynamics. MarketBeat recorded 20 mentions for Accuray and 3 mentions for AngioDynamics. AngioDynamics' average media sentiment score of 0.47 beat Accuray's score of -0.22 indicating that AngioDynamics is being referred to more favorably in the news media.
AngioDynamics received 30 more outperform votes than Accuray when rated by MarketBeat users. However, 65.67% of users gave Accuray an outperform vote while only 60.67% of users gave AngioDynamics an outperform vote.
Accuray presently has a consensus target price of $8.25, indicating a potential upside of 409.26%. AngioDynamics has a consensus target price of $14.25, indicating a potential upside of 127.27%. Given Accuray's higher probable upside, equities analysts plainly believe Accuray is more favorable than AngioDynamics.
Accuray has a net margin of -4.99% compared to AngioDynamics' net margin of -60.21%. AngioDynamics' return on equity of -3.48% beat Accuray's return on equity.
Summary
AngioDynamics beats Accuray on 9 of the 17 factors compared between the two stocks.
Get Accuray News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARAY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
